bioRxivCancer Biology
PITAR, a DNA damage-inducible Cancer/Testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA
S. Jana, M. Mondal, S. Mahale, B. Gupta, K. R. Prasasvi, L. Kandasami, N. Jha, A. Chowdhury, V. Santosh, C. Kanduri, K. Somasundaram
Abstract
In tumors with WT p53, alternate mechanisms of p53 inactivation are reported. Here, we have identified a long noncoding RNA, PITAR (p53 Inactivating TRIM28 associated RNA), as an inhibitor of p53. PITAR is an oncogenic Cancer/testis lncRNA and is highly expressed in glioblastoma (GBM) and glioma stem-like cells (GSC). We establish that TRIM28 mRNA, which encodes a p53-specific E3 ubiquitin ligase, is a direct target of PITAR. PITAR interaction with TRIM28 RNA stabilized TRIM28 mRNA, which resulted in increased TRIM28 protein levels and reduced p53 steady-state levels due to enhanced p53 ubiquitination. DNA damage activated PITAR, in addition to p53, in a p53-independent manner, thus creating an incoherent feedforward loop to inhibit the DNA damage response by p53. While PITAR silencing inhibited the growth of WT p53 containing GSCs in vitro and reduced glioma tumor growth in vivo, its overexpression enhanced the tumor growth in a TRIM28-dependent manner and promoted resistance to Temozolomide. Thus, we establish an alternate way of p53 inactivation by PITAR, which maintains low p53 levels in normal cells and attenuates the DNA damage response by p53. Finally, we propose PITAR as a potential GBM therapeutic target.
- organism: human
- assay: long-read sequencing
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Gain-of-function mutant p53 regulates long-noncoding RNA LINC00643 to modulate HIF1α in glioblastoma
Ying Zhang, Fang Yuan, … Roger Abounader·bioRxiv·Sep 16, 2025
- ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines
M. Lozinski, N. A. Bowden, … P. A. Tooney·bioRxiv·Nov 2, 2023
- p53 knockout drives stage-specific long non-coding RNA reprogramming during human neural differentiation and glioma organoid tumorigenesis.
Fabio Stasi, Alireza Rajabzadeh Manzari, … Massimo De Vittorio·bioRxiv·Sep 18, 2026
- p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
M. Ghosh, S. Saha, … L. A. Martinez·bioRxiv·May 26, 2022
- Role of PARylation and PTEN Mutation on PARP and PARG Inhibitor Efficacy on Glioblastoma
H. Hermanowski, B. Huebert, … D. Quenet·bioRxiv·Jun 30, 2020
- Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage
A. M. Amen, C. Fellmann, … J. F. Costello·Proceedings of the National Academy of SciencesPeer-reviewed·Mar 23, 2021